Navigation Links
Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
Date:11/18/2010

g, including statements related to future preclinical and clinical development plans for its product candidates. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause Oncothyreon's actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of Oncothyreon's product candidates, and the indications for which Oncothyreon's product candidates might be developed. There can be no guarantee that the results of preclinical studies or clinical trials will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation to
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Oncothyreon Reports Third Quarter 2010 Financial Results
2. Oncothyreon to Present at JMP Securities Healthcare Conference
3. ONCOTHYREON ANNOUNCES PRICING OF $14.9 MILLION PRIVATE PLACEMENT
4. ONCOTHYREON APPOINTS JULIE M. EASTLAND AS CHIEF FINANCIAL OFFICER
5. Oncothyreon reports second quarter 2010 financial results
6. Oncothyreon announces second quarter 2010 financial results conference call
7. Oncothyreon announces presentations at upcoming investor conferences in June
8. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
9. Oncothyreon reports full year and fourth quarter 2009 financial results
10. Oncothyreon reports first quarter 2010 financial results
11. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Selexis SA, a ... Research Cell Banks (RCBs) used for drug discovery to ... Banks will include Next-Generation Sequencing (NGS) data ... de-risks biologic manufacturing by ensuring the integrity of the ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014  United ... that Medtronic, Inc. (NYSE: MDT ) has ... and Drug Administration (FDA) for the use of Medtronic,s ... a newly developed catheter) for use with United Therapeutics, ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ā€œPreparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019ā€ provides ... challenges, opportunities, current market trends, and strategies impacting ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... the future will utilise technologies not currently available. An ... carbon nanotubes as interconnects for computer chips. This is ... work from nanotechnology researchers within the Materials Ireland Polymer ... work to develop such junction structure nanotubes used various ...
... DIEGO, Nov. 21 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... 19th Annual,Piper Jaffray Healthcare Conference on Tuesday, November 27, ... is being held at the Pierre Hotel,in New York., ... of Anadys,Pharmaceuticals, Inc., will present an overview of Anadys ...
... SOUTH SAN FRANCISCO, Calif., Nov. 21 ,Exelixis, Inc. (Nasdaq: ... the company,s president and chief executive officer will present ... 1:00 p.m.,ET / 10:00 a.m. PT on Wednesday, November ... may be accessed in the Event,Calendar page under Investors ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference 2
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 The ... it easier to detect and prevent counterfeit microcircuits from ... agency started performing an in-house microcircuit anti-counterfeit initiative dubbed ... purchased microcircuits while increasing their reliability throughout the supply ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... tetrachloroethylene (PCE) -- found to have contaminated drinking water ... to 1985 have been linked to certain diseases and ... the National Research Council, Contaminated Water Supplies at Camp ... about the potential adverse health effects that could occur ...
... b3c newswire / - Dutch biotechnology company ... Scientific Research TNO today announced that they have entered ... viral gene delivery platform SVac . Under this agreement, ... and testing of viral gene delivery systems such as ...
... Society for Microbiology (ASM) Siemens Healthcare Diagnostics ... Melissa B. Miller, Ph.D., D(ABMM), director, Clinical ... Pathology and Laboratory Medicine, and associate director, ... North Carolina (UNC) School of Medicine, Chapel ...
Cached Biology News:Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 2Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 3
... line of digital x-ray detectors from KUBTEC ... complete with 12 to 16 bit digital ... a photodiode array sensor with pixel spacing ... available in low x-ray energies (10-50 kV) ...
The Odyssey Infrared Imaging System is a complete family of products that includes the Odyssey Imager, IRDye labeling reagents and Odyssey software for scan control and data analysis....
... XCAT 50 X-Ray System from KUBTEC is a ... two and three dimensional representation of the specimen ... reconstruction of specimen X-ray images, the micro focus ... level of detail in standard 2D images. The ...
... is the condition in which a lack ... and the various antioxidants. Oxidative stress ... of several diseases, including artherosclerosis, chronic inflammatory ... several antioxidant systems that are very important ...
Biology Products: